Sarepta Therapeutics Hits 52-Week Low After Patient Death
Shares of Sarepta Therapeutics fell after the company said a patient with Duchenne muscular dystrophy died of liver failure after using its Elevidys treatment. The stock opened the market down 22% at $78.61 and slid in early trading as low as $77.69, a new 52-week low.
On March 14, New York State Police arrived at a Steuben County home and learned a man’s in-home caregiver, later identified ...
5hon MSN
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.
For 21 years, Sebastien Beauzile lived with the chronic pain of sickle cell anemia. Now, thanks to a groundbreaking genetic ...
Explore why AI-powered healthcare innovations are enhancing patient care and streamlining medical workflows for better ...
Dominic, 26, fell ill during the second wave of the pandemic in late 2020, and was in intensive care for three months.
Dental patient Michael Beesler, 61, died 3 days after Dr. Scott Schumann's office called 911 reporting he was sedated and not breathing.
Direct-to-patient companies are bringing much-needed disruption to the current healthcare system, challenging payers, ...
Zacks Small Cap Research on MSN6h
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced that the first patient ...
Biotech company Valo Health and AI healthcare firm nference have entered into a multi-year partnership to leverage AI and patient data in drug discovery and development. The collaboration will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback